Plain language summary: the evoke(+) studies of semaglutide for early Alzheimer’s disease

Jeffrey L. Cummings, Alireza Atri, Mary Sano, Henrik Zetterberg, Philip Scheltens, Filip K. Knop, Peter Johannsen, Christian A. Wichmann, Rikke Mortensen Abschneider, Teresa Leon, Jim Taylor, Howard H. Feldman

Open source

DOI: 10.1080/17582024.2026.2666332
Published: 2026-05-20
Container: Neurodegenerative Disease Management
Publisher: Informa UK Limited
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1080/17582024.2026.2666332,
  title = {Plain language summary: the evoke(+) studies of semaglutide for early Alzheimer’s disease},
  author = {Jeffrey L. Cummings and Alireza Atri and Mary Sano and Henrik Zetterberg and Philip Scheltens and Filip K. Knop and Peter Johannsen and Christian A. Wichmann and Rikke Mortensen Abschneider and Teresa Leon and Jim Taylor and Howard H. Feldman},
  year = {2026},
  journal = {Neurodegenerative Disease Management},
  doi = {10.1080/17582024.2026.2666332},
  url = {https://doi.org/10.1080/17582024.2026.2666332}
}

RIS

TY  - JOUR
TI  - Plain language summary: the evoke(+) studies of semaglutide for early Alzheimer’s disease
AU  - Jeffrey L. Cummings
AU  - Alireza Atri
AU  - Mary Sano
AU  - Henrik Zetterberg
AU  - Philip Scheltens
AU  - Filip K. Knop
AU  - Peter Johannsen
AU  - Christian A. Wichmann
AU  - Rikke Mortensen Abschneider
AU  - Teresa Leon
AU  - Jim Taylor
AU  - Howard H. Feldman
PY  - 2026
JO  - Neurodegenerative Disease Management
DO  - 10.1080/17582024.2026.2666332
UR  - https://doi.org/10.1080/17582024.2026.2666332
ER  -

APA

Cummings, J. L., Atri, A., Sano, M., Zetterberg, H., Scheltens, P., Knop, F. K., Johannsen, P., Wichmann, C. A., Abschneider, R. M., Leon, T., Taylor, J., & Feldman, H. H. (2026). Plain language summary: the evoke(+) studies of semaglutide for early Alzheimer’s disease. Neurodegenerative Disease Management. https://doi.org/10.1080/17582024.2026.2666332

Source records

crossref · retrieved 2026-09-25T21:06:18.894Z